Bio Essence Corp
BIOEDrugs in Pipeline
71
Phase 3 Programs
23
Upcoming Catalysts
10
Next Catalyst
This month
Market Overview
Stock performance and key metrics
10 upcoming, 0 past
TCMCB07 Phase 2 Est. Readout
Primary completion for TCMCB07 trial (NCT06937177) in Cancer Weight Loss
Source9 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
buntanetap/posiphen
Early Alzheimers Disease
Meplazumab for Injection
COVID-19
Epoetin Alfa
Anemia in Incident Dialysis Patients
PRX302
Benign Prostatic Hyperplasia
Recombinant humanized anti-PD-1 monoclonal antibody injection
Cervical Cancer
BAT1406
Ankylosing Spondylitis
MCS-2
Lower Urinary Tract Symptoms
JOINTSTEM
Degenerative Arthritis
Tinlarebant
Geographic Atrophy
Glumetinib
Non-Small Cell Lung Cancer
JSKN003
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
BAT2506
Psoriatic Arthritis
Avacincaptad Pegol
Geographic Atrophy
KN026/Placbo Injection
Stomach Cancer
Rotavirus RV3 Vaccine (Bio Farma)
Rotavirus Gastroenteritis
Roxadustat
Chronic Kidney Disease
Measles-Rubella vaccine Bio Farma
Congenital Rubella Infection
SARS-CoV-2 Protein Subunit Recombinant Vaccine
Vaccine Reaction
Tadekinig alfa
NLRC4-MAS
iclaprim
Skin Structures and Soft Tissue Infections
5 Aminolevulinic Acid
5-aminolevulinic Acid
N1539
Pain, Post-operative
Recombinant Hepatitis B + DTP-HB-Hib
Immunogenicity
EIS-12656
Advanced Solid Tumor
PRV-6527
Crohn's Disease
AMB-05X
Tenosynovial Giant Cell Tumor
KB2115
Dyslipidemia
Hemopfin+Green Light
Port-wine Birthmarks
Endostar
Small Cell Lung Cancer
Oral DNA Vaccine
Triple Negative Breast Cancer
CD19-targeted chimeric antigen receptor T-cell
Diffuse Large B Cell Lymphoma
FG-3019
Idiopathic Pulmonary Fibrosis
GB001
Asthma
QHRD107 capsule，Venclexta and Azacitidine
Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML)
BX1000
Neuromuscular Blockade
Timolol maleate PF 0.5% ophthalmic solution
Normal Tension Glaucoma (NTG)
Eprotirome and ezetimibe
Hypercholesterolemia
VBC101
Participants With Advanced Solid Tumor Malignancies
MCS®
Prostate Cancer
ANC-501
Major Depressive Disorder
QLS-111 ophthalmic solution (0.015%)
Normal Tension Glaucoma (NTG)
ROC-101
Pulmonary Arterial Hypertension (PAH)
QLS-101
Primary Open Angle Glaucoma
NECVAX-NEO1
Solid Tumor
Quadrivalent Influenza Vaccine
Safety Issues
QLS-101 ophthalmic solution, 2.0 %
Sturge-Weber Syndrome
human cord blood mononuclear cells
Autism
XPro1595
Alzheimer Disease
ASN008
Dermatitis, Atopic
Verekitug
Chronic Obstructive Pulmonary Disease
SOC + BSB-1001 Dose Escalation Cohort
AML, Adult Recurrent
BEN-2001
Excessive Daytime Sleepiness
SARS-CoV-2 subunit protein recombinant vaccine
COVID-19
Allogeneic umbilical cord mesenchymal stem cells
COVID-19 Infection
BBP-418
LGMD2I
Fruquintinib
Colorectal Cancer
Felzartamab
Immunoglobulin A (IgA) Nephropathy
WIN378
Asthma (Diagnosis)
AAVB-081
Usher Syndrome, Type 1B
AAVB-039
Stargardt Disease
ALA 2.5%
Acne Vulgaris
TCMCB07
Cancer Weight Loss
JMT202 injection
Hypertriglyceridemia
Posiphen
Alzheimer Disease
Human Serum ALbumin/interferon alpha2a
Chronic Hepatitis B
U16
Relapsed or Refractory Non-Hodgkin's Lymphoma
MT-102
Cancer Cachexia
BCG vial vaccine
BCG Vaccination Reaction
TMP-301
Alcohol Use Disorder (AUD)
Enadenotucirev
Solid Tumours of Epithelial Origin
Tofacitinib Citrate
Atopic Dermatitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
buntanetap/posiphen | Phase 3 | Early Alzheimers Disease | - | - |
Meplazumab for Injection | Phase 3 | COVID-19 | - | - |
Epoetin Alfa | Phase 3 | Anemia in Incident Dialysis Patients | - | - |
PRX302 | Phase 3 | Benign Prostatic Hyperplasia | - | - |
Recombinant humanized anti-PD-1 monoclonal antibody injection | Phase 3 | Cervical Cancer | - | - |
BAT1406 | Phase 3 | Ankylosing Spondylitis | - | - |
MCS-2 | Phase 3 | Lower Urinary Tract Symptoms | - | - |
JOINTSTEM | Phase 3 | Degenerative Arthritis | - | - |
Tinlarebant | Phase 3 | Geographic Atrophy | - | - |
Glumetinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
JSKN003 | Phase 3 | Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants | - | - |
BAT2506 | Phase 3 | Psoriatic Arthritis | - | - |
Avacincaptad Pegol | Phase 3 | Geographic Atrophy | - | - |
KN026/Placbo Injection | Phase 3 | Stomach Cancer | - | - |
Rotavirus RV3 Vaccine (Bio Farma) | Phase 3 | Rotavirus Gastroenteritis | - | - |
Roxadustat | Phase 3 | Chronic Kidney Disease | - | - |
Measles-Rubella vaccine Bio Farma | Phase 3 | Congenital Rubella Infection | - | - |
SARS-CoV-2 Protein Subunit Recombinant Vaccine | Phase 3 | Vaccine Reaction | - | - |
Tadekinig alfa | Phase 3 | NLRC4-MAS | - | - |
iclaprim | Phase 3 | Skin Structures and Soft Tissue Infections | - | - |
5 Aminolevulinic Acid | Phase 3 | 5-aminolevulinic Acid | - | - |
N1539 | Phase 3 | Pain, Post-operative | - | - |
Recombinant Hepatitis B + DTP-HB-Hib | Phase 3 | Immunogenicity | - | - |
EIS-12656 | Phase 2 | Advanced Solid Tumor | - | - |
PRV-6527 | Phase 2 | Crohn's Disease | - | - |
AMB-05X | Phase 2 | Tenosynovial Giant Cell Tumor | - | - |
KB2115 | Phase 2 | Dyslipidemia | - | - |
Hemopfin+Green Light | Phase 2 | Port-wine Birthmarks | - | - |
Endostar | Phase 2 | Small Cell Lung Cancer | - | - |
Oral DNA Vaccine | Phase 2 | Triple Negative Breast Cancer | - | - |
CD19-targeted chimeric antigen receptor T-cell | Phase 2 | Diffuse Large B Cell Lymphoma | - | - |
FG-3019 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
GB001 | Phase 2 | Asthma | - | - |
QHRD107 capsule，Venclexta and Azacitidine | Phase 2 | Relapsed/Refractory Acute Myeloid Leukemia (R/R-AML) | - | - |
BX1000 | Phase 2 | Neuromuscular Blockade | - | - |
Timolol maleate PF 0.5% ophthalmic solution | Phase 2 | Normal Tension Glaucoma (NTG) | - | - |
Eprotirome and ezetimibe | Phase 2 | Hypercholesterolemia | - | - |
VBC101 | Phase 2 | Participants With Advanced Solid Tumor Malignancies | - | - |
MCS® | Phase 2 | Prostate Cancer | - | - |
ANC-501 | Phase 2 | Major Depressive Disorder | - | - |
QLS-111 ophthalmic solution (0.015%) | Phase 2 | Normal Tension Glaucoma (NTG) | - | - |
ROC-101 | Phase 2 | Pulmonary Arterial Hypertension (PAH) | - | - |
QLS-101 | Phase 2 | Primary Open Angle Glaucoma | - | - |
NECVAX-NEO1 | Phase 2 | Solid Tumor | - | - |
Quadrivalent Influenza Vaccine | Phase 2 | Safety Issues | - | - |
QLS-101 ophthalmic solution, 2.0 % | Phase 2 | Sturge-Weber Syndrome | - | - |
human cord blood mononuclear cells | Phase 2 | Autism | - | - |
XPro1595 | Phase 2 | Alzheimer Disease | - | - |
ASN008 | Phase 2 | Dermatitis, Atopic | - | - |
Verekitug | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
SOC + BSB-1001 Dose Escalation Cohort | Phase 2 | AML, Adult Recurrent | - | - |
BEN-2001 | Phase 2 | Excessive Daytime Sleepiness | - | - |
SARS-CoV-2 subunit protein recombinant vaccine | Phase 2 | COVID-19 | - | - |
Allogeneic umbilical cord mesenchymal stem cells | Phase 2 | COVID-19 Infection | - | - |
BBP-418 | Phase 2 | LGMD2I | - | - |
Fruquintinib | Phase 2 | Colorectal Cancer | - | - |
Felzartamab | Phase 2 | Immunoglobulin A (IgA) Nephropathy | - | - |
WIN378 | Phase 2 | Asthma (Diagnosis) | - | - |
AAVB-081 | Phase 2 | Usher Syndrome, Type 1B | - | - |
AAVB-039 | Phase 2 | Stargardt Disease | - | - |
ALA 2.5% | Phase 2 | Acne Vulgaris | - | - |
TCMCB07 | Phase 2 | Cancer Weight Loss | - | - |
JMT202 injection | Phase 2 | Hypertriglyceridemia | - | - |
Posiphen | Phase 2 | Alzheimer Disease | - | - |
Human Serum ALbumin/interferon alpha2a | Phase 2 | Chronic Hepatitis B | - | - |
U16 | Phase 2 | Relapsed or Refractory Non-Hodgkin's Lymphoma | - | - |
MT-102 | Phase 2 | Cancer Cachexia | - | - |
BCG vial vaccine | Phase 2 | BCG Vaccination Reaction | - | - |
TMP-301 | Phase 2 | Alcohol Use Disorder (AUD) | - | - |
Enadenotucirev | Phase 2 | Solid Tumours of Epithelial Origin | - | - |
Tofacitinib Citrate | Phase 2 | Atopic Dermatitis | - | - |